PPARγ Ligands Reduce Inflammation in Lung Cells
Author Information
Author(s): Christopher M. Hogan, Thomas H. Thatcher, Ramil E. Sapinoro, Michael N. Gurell, Heather E. Ferguson, Stephen J. Pollock, Carolyn Jones, Richard P. Phipps, Patricia J. Sime
Primary Institution: University of Rochester
Hypothesis
PPARγ ligands would exhibit anti-inflammatory effects in human lung fibroblasts.
Conclusion
PPARγ ligands have potent anti-inflammatory effects on human lung fibroblasts, primarily through a PPARγ-independent mechanism.
Supporting Evidence
- PPARγ ligands inhibited the production of IL-6 and MCP-1 in lung fibroblasts.
- CDDO and 15d-PGJ2 were more effective than rosiglitazone in reducing inflammatory mediator production.
- The anti-inflammatory effects of CDDO and 15d-PGJ2 were not reversed by the PPARγ antagonist GW9662.
Takeaway
Some special molecules can help calm down inflammation in lung cells, which is important for treating lung diseases.
Methodology
Primary human lung fibroblasts were treated with PPARγ ligands and inflammatory stimuli, and the production of inflammatory mediators was measured.
Limitations
The study primarily focuses on in vitro results, which may not fully translate to in vivo conditions.
Participant Demographics
Primary human lung fibroblasts derived from patients undergoing surgical resection for benign hamartoma.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website